Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanine SCHEMBL2529420 | 1.00 | PNP (0.72) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL79001 | 1.00 | PNP (0.72) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL23576542 | 0.94 | PNP (0.63) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL19991865 | 0.93 | PNP (0.62) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL5579240 | 0.92 | PNP (0.60) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL7211609 | 0.92 | PNP (0.60) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL37966 | 0.91 | PNP (0.59) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL20518478 | 0.88 | PNP (0.55) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL17597606 | 0.88 | PNP (0.55) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL23880590 | 0.88 | PNP (0.55) | PNPALDH1A1KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839627-B2 | Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder | NEUROVANCE, INC. (US) | 2017-12-12 | — | — | US | claimed |
| US-20160303076-A1 | NOVEL METHODS | NEUROVANCE, INC. (US) | 2016-10-20 | — | — | US | claimed |
| WO-2016040602-A1 | REDUCED REPRESENTATION BISULFITE SEQUENCING USING URACIL N-GLYCOSYLASE (UNG) AND ENDONUCLEASE IV | EPICENTRE TECHNOLOGIES CORPORATION (US) | 2016-03-17 | — | — | WO | claimed |
| WO-2015089111-A1 | NOVEL METHODS | NEUROVANCE, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| US-20080300187-A1 | MUTATED HOXB4 PROTEINS WITH IMPROVED STABILITY, AND METHODS OF USE THEREOF | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2008-12-04 | — | — | US | claimed |
| EP-4366828-A1 | METHODS FOR TREATING NERVOUS SYSTEM DISORDERS WITH ANTIPURINERGIC AGENTS | Paxmedica, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240100191-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230390223-A1 | ADMINISTRATION OF ANTIPURINERGIC COMPOSITIONS FOR TREATING NERVOUS SYSTEM DISORDERS | PAXMEDICA, INC. (US) | 2023-12-07 | — | — | US | disclosed |
| US-20230390226-A1 | INTRANASAL ADMINISTRATION OF SURAMIN FOR TREATING NERVOUS SYSTEM DISORDERS | PAXMEDICA, INC. (US) | 2023-12-07 | — | — | US | disclosed |
| US-11759533-B2 | Methods and compositions for modulating gene expression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-09-19 | — | — | US | disclosed |
| EP-4228642-A1 | ADMINISTRATION OF ANTIPURINERGIC COMPOSITIONS FOR TREATING NERVOUS SYSTEM DISORDERS | Paxmedica, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4229035-A1 | INTRANASAL ADMINISTRATION OF SURAMIN FOR TREATING NERVOUS SYSTEM DISORDERS | Paxmedica, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20150307487-A1 | SMALL MOLECULES TARGETING REPEAT r(CGG) SEQUENCES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2015-10-29 | — | — | US | disclosed |
| WO-2015089111-A1 | NOVEL METHODS | NEUROVANCE, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2014036395-A1 | SMALL MOLECULES TARGETING REPEAT r(CGG) SEQUENCES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-03-06 | — | — | WO | disclosed |
| US-8039436-B2 | Mutated HOXB4 proteins with improved stability, and methods of use thereof | British Columbia Caner Agency Branch (CA) | 2011-10-18 | — | — | US | disclosed |
| US-20080300187-A1 | MUTATED HOXB4 PROTEINS WITH IMPROVED STABILITY, AND METHODS OF USE THEREOF | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2008-12-04 | — | — | US | disclosed |
| US-20070174924-A1 | Transgenic mice containing TRP gene disruptions | DELTAGEN, INC. | 2007-07-26 | — | — | US | disclosed |
| EP-1224199-A1 | TRANSGENIC MICE CONTAINING TRP GENE DISRUPTIONS | Deltagen, Inc. (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001030798-A1 | TRANSGENIC MICE CONTAINING TRP GENE DISRUPTIONS | DELTAGEN, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307487-A1 | SMALL MOLECULES TARGETING REPEAT r(CGG) SEQUENCES | HNRNPM, RBM39, FUS | PNP 2459/4885ALDH1A1 4710/4885KDM4E 2017/4885 |
| US-20160303076-A1 | NOVEL METHODS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, BCL6, MALT1 | PNP 972/4885ALDH1A1 474/4885KDM4E 2048/4885 |
| US-11759533-B2 | Methods and compositions for modulating gene expression | BRD4, BICRA, BRDT | PNP 4415/4885ALDH1A1 4526/4885KDM4E 923/4885 |
| US-20230390223-A1 | ADMINISTRATION OF ANTIPURINERGIC COMPOSITIONS FOR TREATING NERVOUS SYSTEM DISORDERS | ADK, SNRK, ABCC9 | PNP 545/4885ALDH1A1 2212/4885KDM4E 1700/4885 |
| US-20230390226-A1 | INTRANASAL ADMINISTRATION OF SURAMIN FOR TREATING NERVOUS SYSTEM DISORDERS | SLC18A2, SLC18A3, CLN6 | PNP 1520/4885ALDH1A1 1990/4885KDM4E 4391/4885 |
| US-20240100191-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | BRD4, BICRA, BRDT | PNP 4421/4885ALDH1A1 4538/4885KDM4E 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.